Lusutrombopag: A Review in Thrombocytopenia in Patients with Chronic Liver Disease Prior to a Scheduled Procedure
- 81 Downloads
Lusutrombopag (Mulpleta®), an orally bioavailable, small molecule thrombopoietin receptor agonist, is approved for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. In placebo-controlled phase 3 clinical trials, lusutrombopag significantly increased the proportion of patients who did not require a platelet transfusion prior to the procedure or rescue therapy for bleeding up to 7 days after the scheduled procedure. Lusutrombopag also significantly increased the proportion of patients who were responders (i.e. had a platelet count ≥ 50 × 109/L and an increase of ≥ 20 × 109/L from baseline) compared with placebo. Lusutrombopag is well tolerated, with headache being the most common adverse reaction in lusutrombopag recipients in clinical trials. Thus, lusutrombopag represents a promising emerging therapeutic option for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
During the peer review process, the manufacturer of lusutrombopag was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
Matt Shirley, Emma McCafferty and Hannah Blair are salaried employees of Adis International Ltd/Springer Nature, are responsible for the article content and declare no relevant conflicts of interest.
- 1.National Heart Lung and Blood Institute. Thrombocytopenia. 2019. http://www.nhlbi.nih.gov/health-topics/thrombocytopenia. Accessed 22 Aug 2019.
- 11.Miller JB, Figueroa EJ, Haug RM, et al. Thrombocytopenia in chronic liver disease and the role of thrombopoietin agonists. Gastroenterol Hepatol (N Y). 2019;15(6):326–32.Google Scholar
- 12.US FDA. Mulpleta® (lusutrombopag tablets) for oral use: US prescribing information. 2018. http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Accessed 22 Aug 2019.
- 13.European Medicines Agency. Lusutrombopag Shionogi: summary of product characteristics. 2019. http://www.ema.europa.eu. Accessed 22 Aug 2019.
- 14.Japanese Pharmaceuticals and Medical Devices Agency. Lusutrombopag tablets 3 mg: Japanese prescribing information. 2015. http://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/340018_3399010F1022_1_02. Accessed 7 Jan 2019.
- 16.Yoshida H, Yamada H, Nogami W, et al. Development of a new knock-in mouse model and evaluation of pharmacological activities of lusutrombopag, a novel, nonpeptidyl small-molecule agonist of the human thrombopoietin receptor c-Mpl. Exp Hematol. 2018;59(30–9):e2.Google Scholar
- 21.Alkhouri N, Imawari M, Izumi N, et al. Safety and efficacy of lusutrombopag for treatment of thrombocytopenia in subjects with HCC undergoing planned invasive procedures: combined analysis of L-PLUS 1 and L-PLUS 2 trials [abstract no. 0949 plus poster]. In: AASLD—The Liver Meeting®. 2018.Google Scholar
- 23.Sasaki R, Shiino C, Imawari M, et al. Safety and effectiveness of lusutrombopag in Japanese chronic liver disease patients with thrombocytopenia undergoing invasive procedures: interim results of a postmarketing surveillance. Hepatol Res. 2019. https://doi.org/10.1111/hepr.13392.CrossRefPubMedGoogle Scholar
- 25.US FDA. Doptelet® (avatrombopag) tablets, for oral use: US prescribing information. 2019. http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Accessed 22 Aug 2019.
- 26.European Medicines Agency. Doptelet (avatrombopag): summary of product characteristics. 2019. http://www.ema.europa.eu. Accessed 30 Aug 2019.
- 28.Katsube T, Shimizu R, Fukuhara T, et al. Pharmacokinetic/pharmacodynamic modelling and simulation of lusutrombopag, a novel thrombopoietin receptor agonist, for the treatment of thrombocytopenia in patients with chronic liver disease undergoing invasive procedures. Clin Pharmacokinet. 2019. https://doi.org/10.1007/s40262-019-00770-4.CrossRefPubMedGoogle Scholar